Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic resection with perioperative propranolol and etodolac (Phase II randomized trial)
2018-000415-25Phase 2Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of propranolol and etodolac in pancreatic cancer (PC) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Safety endpoints. Started Jun 2018; status: terminated.
02
Drugs
propranololetodolac
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2018-000415-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000415-25.